FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

He completed a 14-question intake on Hims.com and received a bottle of finasteride pills days later. He never spoke to a doctor. Soon after taking the medicine, Millich said he felt strange symptoms.

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Hims, Inc. has an A+ rating from the BBB as of February 2025. Most negative reviews are about products related to sexual health rather than hair loss. Many reviewers complain that they were still ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever ...

Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to ...

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $27.00 price ...